Protecting research results before commercialization requires a layered approach combining legal tools, contractual safeguards, and strategic timing. The right combination depends on the nature of your research, the number of parties involved, and how you plan to bring the results to market. Below, we unpack the most important questions researchers and organizations face when securing their innovations.
What types of intellectual property can protect research results?
Research results can be protected through several types of intellectual property, including patents, trade secrets, copyrights, and trademarks. Each tool serves a different purpose, and most organizations use more than one in combination to build a comprehensive protection strategy around their innovations.
- Patents grant exclusive rights to a novel invention for a defined period, typically 20 years, preventing others from making, using, or selling the invention without a license.
- Trade secrets protect confidential business information, formulas, processes, or data that give a competitive advantage, as long as reasonable steps are taken to keep them secret.
- Copyrights automatically protect original written works, software code, datasets, and research reports from the moment of creation.
- Trademarks protect brand identifiers associated with a product or service that emerges from the research, becoming more relevant as commercialization progresses.
For most research and technology organizations, patents and trade secrets carry the heaviest weight during the pre-commercial phase. Copyrights tend to apply more broadly to documentation and software outputs, while trademarks come into play later in the commercialization journey.
When should you file for IP protection during the research process?
You should file for IP protection as early as possible, ideally before any public disclosure, publication, or presentation of the research. In most jurisdictions, public disclosure before filing can invalidate a patent application, making timing one of the most critical decisions in the entire R&D protection process.
A practical rule of thumb is to begin the IP evaluation process once a research result shows clear potential for practical application, not after the full project is complete. This means building IP checkpoints into your research timeline rather than treating protection as a final step.
Key moments to trigger an IP review include:
- When a novel method, material, or process is identified that solves a defined problem
- Before submitting a paper for peer review or presenting at a conference
- When entering into collaboration discussions with external partners or industry contacts
- Before applying for follow-on funding that may require disclosure of results
Filing a provisional patent application can be a useful interim step, giving you a 12-month window to refine the invention and assess commercial viability before committing to a full application.
How does a non-disclosure agreement protect pre-commercial research?
A non-disclosure agreement (NDA) protects pre-commercial research by creating a legally binding obligation for all parties to keep shared information confidential. It prevents collaborators, potential partners, or evaluators from disclosing or using your research results without authorization, giving you a controlled environment to explore opportunities without triggering public disclosure.
NDAs are especially important in the early stages of technology transfer discussions, when you need to share sensitive data or proof-of-concept results with potential industry partners before any formal agreement is in place. Without an NDA, sharing that information could compromise your ability to file for patent protection or undermine your competitive position.
A well-drafted NDA should clearly define what constitutes confidential information, set the duration of the obligation, specify permitted uses of the information, and outline consequences for breach. Mutual NDAs, which bind both parties, are common in research collaboration contexts where both sides may be sharing proprietary knowledge.
What is the difference between a patent and a trade secret for research results?
The key difference is that a patent provides public, time-limited legal exclusivity in exchange for full disclosure of the invention, while a trade secret protects information indefinitely through confidentiality, with no disclosure required. Choosing between them depends on whether your research result is patentable, how long you need protection, and whether disclosure would harm your competitive position.
When a patent makes sense
Patents are the stronger choice when the invention is clearly novel and inventive, when you want enforceable exclusivity in specific markets, and when the technology will be visible in the final product anyway. A patent gives you the legal right to stop others from using the invention even if they independently develop the same solution.
When a trade secret makes sense
Trade secrets are preferable when the research result is a process or formula that can be kept hidden in practice, when the commercial life of the innovation may outlast a patent term, or when the cost and complexity of patent prosecution across multiple jurisdictions is not justified. The risk is that independent discovery or reverse engineering by a competitor is entirely legal and will end the protection immediately.
Many organizations use both in parallel, patenting the core invention while protecting surrounding know-how, manufacturing processes, or proprietary data as trade secrets.
Who owns the IP when research involves multiple organizations?
Ownership of IP in multi-party research is determined by the agreements signed before the research begins. Without a clear contractual framework, IP ownership defaults to national law, which varies significantly by jurisdiction and can create disputes that delay or block commercialization entirely.
In collaborative research settings, ownership arrangements typically fall into one of three models:
- Single owner: One party owns all IP, with others receiving licenses. This simplifies commercialization but requires the non-owning parties to negotiate license terms carefully.
- Joint ownership: All contributing parties share ownership. This sounds equitable but can create complications, since in many jurisdictions joint owners can independently license or exploit the IP without the other owners’ consent.
- Consortium agreement: A dedicated IP management structure is established for the collaboration, with defined rules for ownership, licensing, revenue sharing, and commercialization rights.
The most effective approach is to address IP ownership explicitly in a collaboration agreement or consortium contract before the research starts. This should cover who owns foreground IP (results generated during the project), how background IP (existing knowledge each party brings) is licensed, and what happens if a party exits the collaboration early.
How do you move from IP protection to successful commercialization?
Moving from IP protection to successful commercialization requires a structured technology transfer process that connects your protected research to market-ready applications through licensing, spin-off creation, or direct industry partnerships. IP protection is the foundation, but commercialization depends on identifying the right pathway and the right partners to bring the innovation to scale.
The core steps in this transition include:
- IP valuation: Assess the commercial value of the protected research to inform licensing terms and investment decisions.
- Market mapping: Identify industries, sectors, and specific companies that could benefit from or build on the research results.
- Licensing or assignment: Grant rights to use the IP to a commercial partner in exchange for royalties or a lump-sum payment, or transfer ownership outright.
- Spin-off or startup formation: Create a new company to commercialize the IP directly, often with equity shared between the research organization and founding team.
- Industry partnership: Engage directly with established companies through co-development agreements that take the research from prototype to product.
Across all these pathways, access to the right network is one of the most important accelerators. Research organizations that are connected to a broad ecosystem of industry partners, funding bodies, and fellow institutions are significantly better positioned to find the right commercialization route quickly.
How WAITRO supports IP protection and research commercialization
We help research and technology organizations navigate the full journey from protecting research results to bringing them to market. Through our global network of over 180 member organizations, research universities, and industry partners, we create the connections and frameworks that make successful commercialization possible.
Here is what we offer organizations working on institutional capacity building and research commercialization:
- Cross-border partnership facilitation: We connect RTOs with industry partners, co-investors, and technology transfer specialists across regions, opening doors that would otherwise take years to unlock independently.
- Capacity development programs: We provide practical tools, training, and guidance to strengthen your organization’s ability to manage IP, negotiate agreements, and structure commercialization pathways.
- Public-private partnership access: We facilitate participation in publicly funded collaborations and PPPs where IP frameworks and commercialization strategies are built into the project design from the start.
- Knowledge sharing across the network: Members gain access to the collective expertise of leading organizations like Fraunhofer, Leitat, and JITRI, including their experience in technology transfer and research commercialization.
If your organization is ready to move from research to real-world impact, we invite you to explore WAITRO membership and discover how our global platform can strengthen your commercialization strategy.
